AI-generated analysis. Always verify with the original filing.
Whitehawk Therapeutics Inc filed an 8-K on March 12, 2026, under Item 2.02 announcing results of operations via Press Release in Exhibit 99.1. Item 2.02 and Item 9.01 are not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
Event Type
Disclosure
Mandatory
Variant
8-K
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Ex
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated March 12, 2026 104 Cover Page Interactive Data File (embedd